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Renal disease in pregnancy may cause a feeling 
of trepidation, even in the most experienced 
physician, and may take several forms. Pregnancy 
may be the first medical review for women with 
a previously undiagnosed renal problem. Patients 
may have pre-existing renal disease, e.g. diabetic nephropathy. 
Additionally, women with renal transplants and renal diseases, e.g. 
lupus nephritis, require immunosuppression. Pregnancy outcomes 
in renal disease are determined by baseline creatinine levels, 
hypertension and degree of proteinuria. The risk of progression of 
chronic kidney disease (CKD) and maternal and fetal complications 
increases as the renal function worsens, and patients need to 
be counselled, preferably prior to conception. Pre-existing renal 
disease predisposes to pre-eclampsia, a condition occurring in 
up to 5% of pregnancies, making it one of the most common 
complications of pregnancy. A multidisciplinary team approach 
involving a physician/nephrologist and an obstetrician is essential 
to assess and care for pregnant women with kidney disease.
Normal physiological adaptations of 
pregnancy 
The kidneys increase in length (1 - 2  cm) and volume (70%) with 
dilation of the calyces, renal pelvis and ureters, features which 
are more prominent on the right. By the third trimester, 80% of 
women show evidence of hydronephrosis, which predisposes to 
urinary stasis, increasing the risk of urinary tract infections.[1] 
There is hormonal dilatation of the systemic blood vessels, leading 
to a decrease in systemic vascular resistance and a physiological 
lowering of blood pressure, especially during the first and second 
trimesters. Thereafter, there is a steady return of blood pressure to 
pre-pregnancy levels until term. 
Plasma volume increases significantly, leading to a 30 - 50% 
increase in cardiac output and resulting in a steady increase in 
renal blood flow (50% by the mid-second trimester). This increases 
the glomerular filtration rate (GFR) and gives rise to frequency 
and nocturia, resulting in decreased creatinine blood levels. The 
increased vascularity of the kidneys makes a renal biopsy beyond 32 
weeks risky. Despite the increase in renal blood flow, the pressure 
within the glomerulus remains unaltered owing to compensatory 
effects on the afferent and efferent arteriole, but this only occurs 
in a normal kidney. Any pre-existing disease in the kidney will be 
accelerated, often with deterioration in renal function.
Pregnancy also affects the renal tubules. There is decreased 
reabsorption of glucose and bicarbonate, leading to glycosuria 
and bicarbonaturia. Despite the loss of bicarbonate, there is a 
persistent alkalosis owing to an increased respiratory rate. There is 
hypercalciuria, although the risk of renal stones is not increased as 
inhibitors of stone formation also increase. It is also common to find 
mild proteinuria, <300  mg/d, which may remain up to 6 months 
postpartum. Isolated pyuria is common and disappears by 3 months 
postpartum. Serum sodium may decrease by 4 - 5 mEq/L and serum 
osmolality falls to a new osmotic setpoint of about 270 mOsm/kg. 
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Renal disease in pregnancy may cause a feeling of trepidation, even in the most experienced physician. However, before disease can be 
established, it is important to understand the substantial physiological changes that may occur during a normal pregnancy. Renal disease 
may take several forms and pregnancy may be the first medical review for women with a previously undiagnosed renal problem. Patients 
may have pre-existing renal disease, e.g. diabetic nephropathy. Additionally, women with renal transplants and renal diseases, e.g. lupus 
nephritis, require immunosuppression. Hypertensive disorders of pregnancy, including pre-eclampsia, are the commonest medical 
complications in pregnancy, and remain the most prevailing direct cause of maternal mortality in South Africa (SA). Both pre-existing 
hypertension and renal disease increase the risk of pre-eclampsia, which predisposes to preterm delivery, and maternal morbidity and 
mortality. 
Pregnancy outcomes in renal disease are determined by baseline creatinine levels, hypertension and degree of proteinuria. The risk of 
progression of chronic kidney disease increases as renal function worsens. In SA, this is complicated by restricted access to dialysis in the 
state sector. To ensure the best outcome for mother and child, pre-pregnancy counselling and review of medication are essential. Renal 
patients and those with hypertension are at high risk of complications, and regular antenatal assessments by a multidisciplinary team are 
required to monitor blood pressure, proteinuria, diabetes control and fetal wellbeing.
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Important renal adaptations in pregnancy
• Increase in kidney size 1 - 2 cm
• Dilatation of the urinary collecting system
• Increase in renal blood flow
• Increase in glomerular filtration rate
• Decrease in creatinine
• Glycocosuria and bicarbonaturia
• Decrease in plasma sodium and osmolality
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Estimating glomerular filtration rate 
in pregnancy
The modification of diet in renal disease (MDRD) is a creatinine-
based formula that measures GFR. It has become a standard clinical 
method used to estimate renal function in patients with CKD. 
The use of this formula has not been well studied in the pregnant 
population and guidelines for its use exclude pregnant women,[2] 
because creatinine falls in pregnancy owing to a pregnancy-induced 
increase in GFR and haemodilution from plasma expansion. The 
MDRD formula is also known to be inaccurate once the GFR is >60 
ml/min/m2, even in non-pregnant women. This inaccuracy is more 
pronounced in pregnancy.[3] Weight-based formulas, such as those 
used in the Cockroft-Gault method, are likely to overestimate GFR 
because the increased body weight in pregnancy does not typically 
reflect increased muscle mass or creatinine production.[4] Given this, 
24-hour urine collection for creatinine clearance remains the gold 
standard for GFR estimation in pregnancy.
Estimating proteinuria in pregnancy 
Proteinuria needs to be measured first to monitor pre-existing 
proteinuria, which may increase substantially during pregnancy. 
The protein-creatinine ratio (PCR) is the preferred method for 
quantitating proteinuria in the non-pregnant state[5] and its use is 
recommended to monitor pre-existing proteinuria during pregnancy. 
The second indication is for the diagnosis of pre-eclampsia, which 
is defined as the new onset of hypertension (blood pressure (BP) 
>140/90 mmHg) and proteinuria (>300 mg protein in a 24-hour 
urine collection) after 20 weeks’ gestation.[6] Although there are 
limitations to 24-hour urine collections, the use of PCR for the 
diagnosis of pre-eclampsia has been controversial, with discordant 
conclusions compared with 24-hour urine collections.[7]
Specific diseases of the kidney
Hypertensive disorders, including pre-eclampsia
Hypertensive disorders of pregnancy are the commonest medical 
complications in pregnancy, and remain the most prevailing direct 
cause of maternal mortality in SA.[8] In the UK, 3 - 5%  of pregnant 
women have hypertension that predates conception.[9] It is more 
common in advanced maternal age, obesity and blacks.[10] A secondary 
cause should be excluded if appropriate. About 22 - 25% of women 
with pre-existing hypertension are likely to develop pre-eclampsia.[11] 
Pregnancy-induced hypertension is defined as a BP >140/90 mmHg 
arising after 20 weeks of gestation and returning to normal within 
6 weeks postpartum.[6] Pre-eclampsia is a multisystem disorder that 
is commonly associated with oedema and hyperuricaemia. It is a 
leading cause of maternal mortality and morbidity in developed[12] 
and developing countries, where it continues to claim the lives of 
>60 000 mothers every year.[13]
Pre-eclampsia appears to be initiated by abnormal implantation 
of the placenta, leading to hypoperfusion and ischaemia. There is 
accumulating evidence supporting the release of several placental 
anti-angiogenic factors including soluble fms-like tyrosine kinase-19 
(sFlt1) and its synergist, soluble endoglin (sEng). These anti-
angiogenic factors are induced or exacerbated by placental ischaemia, 
with sFlt1 being a circulating antagonist to both vascular endothelial 
growth factor (VEGF) and placental growth factor. Circulating VEGF 
is mopped up by sFlt1to prevent the former’s protective effects on 
the endothelium. When administered to pregnant rats, sFlt1 and 
sEng produce a syndrome resembling that of HELLP (haemolysis, 
elevated liver enzymes, and low platelets).[14,15] Subsequent studies 
have demonstrated the role of these anti-angiogenic factors in the 
pathogenesis of pre-eclampsia in humans.[16-18]
Clinically, vascular endothelial dysfunction and microangiopathy are 
present in the mother, but not in the fetus. The predominant target 
organ may be the brain (seizures or eclampsia), the liver (HELLP 
syndrome), or the kidney (glomerular endotheliosis and proteinuria). 
Predisposing factors include pre-existing hypertension, CKD, obesity, 
diabetes mellitus, thrombophilias, and multiple gestations.[19] These 
women may be more susceptible to endothelial dysfunction and 
hence more responsive to anti-angiogenic factors.  
Screening for pre-eclampsia has the greatest impact on clinical 
outcomes, but to date there is no effective preventive treatment. 
Although two large meta-analyses have suggested a small, but 
significant, overall benefit in patients treated with aspirin,[20,21] the 
delivery of the fetus is currently the only definitive treatment.
Considerable evidence suggests that pre-eclampsia predisposes 
women to late cardiac and vascular diseases[22] and also increases 
the risk of subsequent CKD. The risk is greater if a pre-eclamptic 
pregnancy results in the birth of a low-birth-weight or preterm infant 
or if pre-eclampsia occurs in more than one pregnancy.[23] 
Chronic kidney disease in pregnancy 
Women with CKD who become pregnant are at increased risk for 
adverse maternal and fetal outcomes, including a rapid decline in 
renal function, intrauterine grown retardation, perinatal mortality 
and pre-eclampsia.[24,25] The major determinants of outcome are 
pre-existing proteinuria, hypertension, urinary tract infection and 
degree of renal dysfunction. Obstetric outcomes are also partly 
related to the level of available neonatal care. Very importantly, 
maternal renal function may decline irreversibly proportional to the 
level of pre-existing dysfunction. In a SA setting, this is an important 
consideration as access to dialysis is limited in the state sector.
The stress of increased renal blood flow and inability of the glomerulus 
to regulate intraglomerular pressure, which normally remains unaltered 
during pregnancy, may exacerbate renal damage in pre-existing disease. 
Managing dialysis and renal 
transplant patients 
CKD is generally characterised by menstrual disturbances and infertility, 
and is reversed by transplantation but not by dialysis.[27] Although 
conception in patients on dialysis is unusual, it is not impossible, and 
adequate contraception remains important. When pregnancy does 
occur, it needs to be co-managed by a nephrologist and an obstetrician 
as significant changes in management are required to improve maternal 
and neonatal outcomes. Transplant patients should also be co-managed 
as immunosuppressive drugs may need to be altered and their plasma 
levels will need to be carefully monitored. Pregnant women who have a 
transplanted kidney with renal dysfunction should be considered in the 
same way as other patients with CKD. 
Pregnancy-induced acute kidney 
injury 
Acute kidney injury (AKI) in pregnancy may be caused by any of 
the disorders leading to renal failure in the general population, e.g. 
Maternal renal function declines proportional to the level of 
pre-existing renal dysfunction[24,26]
• Creatinine <123 µmol/L: considered  safe 
• Creatinine 130 - 170 µmol/L: 40% have deterioration in renal 
function, of whom half recover 
• Creatinine >176 µmol/L: two-thirds have an accelerated decline 
in renal function and one-third require dialysis
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acute tubular necrosis (ATN) due to infection, glomerulonephritis or 
drug toxicity. There are, however, pregnancy-related complications 
characteristic of each trimester that can result in renal failure.[28,29] 
Early in pregnancy the most common problems are pre-renal disease 
due to hyperemesis gravidarum or ATN following a septic abortion. 
In the second and third trimesters, pregnancy-specific conditions, 
e.g. pre-eclampsia, HELLP syndrome, acute fatty liver of pregnancy, 
haemolytic-uraemic syndrome  and  thrombotic thrombocytopenic 
purpura, can be complicated by acute renal failure. At delivery, 
placental abruption can be associated with severe ATN and bilateral 
cortical necrosis. The management of AKI is similar to that in 
a non-pregnant patient, with fluid management being especially 
important, particularly in the context of pre-eclampsia, as the vascular 
endothelium is very leaky. Potential nephrotoxins such as the non-
steroidal anti-inflammatory drugs (NSAIDs) and aminoglycosides 
should be used with caution throughout the pregnancy.
Managing the complicated patient  
Diabetic nephropathy
Diabetic nephropathy is frequently encountered during pregnancy. Pre-
pregnancy counselling is important, as obstetric and renal outcomes are 
determined by the degree of peripartum CKD. There is no increased 
risk of overt nephrophathy or end-stage renal disease in women with 
normal renal function at conception.[30] However, diabetic nephropathy 
is associated with a 2 - 4-fold increased risk of pre-eclampsia, preterm 
delivery and perinatal death.[31] Management includes low-dose aspirin 
from the first trimester to reduce the risk of pre-eclampsia, regular renal 
function monitoring, good BP control and tight glycaemic control. 
Lupus nephritis 
Women with lupus nephritis should be advised to conceive after a 
6-month period of quiescent disease. Predictors of poor obstetric 
outcomes include active disease at conception and early pregnancy, 
>0.5 g protein/24 h, CKD stage >3, hypertension and antiphospholipid 
antibodies. There is also an increased risk of pre-eclampsia. 
Extra-renal disease flare-ups are more common in the second and 
third trimesters, and postpartum flare-ups have been described.[32]
Flare-ups can be managed with corticosteroids. Maintenance 
therapy with azathioprine and hydroxychloroquine is considered 
safe. Tacrolimus and cyclosporin can be used in pregnancy with 
therapeutic drug level monitoring. Differentiating between a flare-
up of lupus nephritis and pre-eclampsia may be challenging. A low 
C3/C4, a rising double-stranded DNA (dsDNA) and an active urine 
sediment with red cell casts are suggestive of  recurrence of lupus. 
Drugs and the kidney  
Methyldopa is the first-line agent of choice to treat hypertension 
in pregnancy and has a well-documented safety profile,[33,34] while 
the calcium channel blocker, nifedipine,[35] and the selective a1- and 
non-selective b-adrenergic receptor-blocker, labetalol, also appear 
to be safe.[36] Diuretics are generally not recommended as they 
can theoretically compromise the pregnancy-associated increase 
in plasma volume, although outcome data have not supported 
these concerns.[37] Angiotensin-converting enzyme (ACE) inhibitors 
are teratogenic and can cause renal dysgenesis, oligohydramnios, 
calvarial and pulmonary hypoplasia, intrauterine growth restriction, 
and neonatal renal failure, leading to death of the fetus as early as 
the first trimester.[38,39] Similar anomalies have been reported with 
angiotensin II receptor blockers (ARBs).[40] ACE inhibitors and ARBs 
should be discontinued prior to conception, with appropriate birth 
control measures while on these agents.
Calcineurin inhibitors, glucocorticosteroids and azathioprine 
are the mainstay of safe immunosuppressive therapy in pregnant 
transplant recipients and lupus patients. Mycophenolate mofetil has 
been reported to cause developmental toxicity, malformations, and 
intrauterine death in animals, with growing evidence confirming its 
teratogenic effects in humans. The drug should be discontinued 6 
weeks before conception. 
Conclusion 
Because there are substantial physiological changes that occur in a 
normal pregnancy, it is necessary to understand these in order to 
determine whether the kidney developed disease during pregnancy. 
Both pre-existing hypertension and renal disease increase the risk of 
adverse pregnancy outcomes and increase the risk of pre-eclampsia, 
which predisposes to preterm delivery. Pregnancy in a patient with 
CKD may cause progression of renal failure, and in the SA setting 
this is complicated by restricted access to dialysis in the state sector. 
To ensure the best outcome for mother and child, pre-pregnancy 
counselling is essential. Attention must be paid to the numerous 
teratogenic drugs that are commonly used to treat hypertension and 
the immunosuppression necessary to treat renal transplant recipients 
and those with glomerulonephritis (e.g. lupus nephritis). Patients 
with renal disease and hypertension are at high risk of complications 
and regular antenatal assessments are required that should involve a 
multidisciplinary team to monitor BP, proteinuria, diabetic control 
and fetal wellbeing . 
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